Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

GnRH antagonist MoA: Finding a balance between level of estradiol suppression, associated symptoms, and BMD protection High dose GnRH antagonist & add-back Moderate dose GnRH antagonist & no add-back BMD: Bone mineral density ESSS: Endometriosis symptom severity score • Estradiol measured at 1-2 months after treatment initiation was shown to be a reliable predictor of 6-month BMD change. • Estradiol range between 20 and 60 pg/mL targets optimal treatment of endometrial pain while minimizing BMD effects. • This treatment approach will require use of add-back hormone replacement therapy only as needed. Integrated Pharmacometrics and Systems Pharmacology Model-Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis Riggs MM et al. 2012 CPT: Pharmacometrics & Systems Pharmacology 1, e11.